12 Sept 2013
French drugmaker Sanofi and Danish partner Zealand Pharma have announced the withdrawal of a US marketing application for lixisenatide, to resubmit when results from a cardiovascular study become available, expected in 2015.
New Awards Committee Chair
29 Jan 2025
Society for Endocrinology endorses landmark guidelines for childhood pituitary tumour care
29 Jan 2025
Announcing the Winners of the SfE Emerging Researcher Lectures 2025
23 Jan 2025
Congratulations to the awardees of our third round of 2024 grants
22 Jan 2025